Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CetuGEX vs Cetuximab in Recurrent/Metastatic SCCHN
NCT02052960Phase 2Completed
- Sponsor
- Glycotope
- Start
- Feb 2014
- Primary completion
- Aug 2017
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of tomuzotuximab in head and neck squamous cell carcinoma (HNSCC), sponsored by Glycotope. Started Feb 2014; status: completed.
02
Drugs
tomuzotuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02052960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02052960.